The Coronavirus Immunotherapeutic Consortium (CoVIC) conducted side-by-side comparisons of over 400 anti-SARS-CoV-2 spike therapeutic antibody candidates contributed by large and small companies as well as academic groups on multiple continents. Nine reference labs analyzed antibody features, including in vivo protection in a mouse model of infection, spike protein affinity, high-resolution epitope binning, ACE-2 binding blockage, structures, and neutralization of pseudovirus and authentic virus infection, to build a publicly accessible dataset in the database CoVIC-DB. High-throughput, high-resolution binning of CoVIC antibodies defines a broad and predictive landscape of antibody epitopes on the SARS-CoV-2 spike protein and identifies features associated with durable potency against multiple SARS-CoV-2 variants of concern and high in vivo efficacy. Results of the CoVIC studies provide a guide for selecting effective and durable antibody therapeutics and for immunogen design as well as providing a framework for rapid response to future viral disease outbreaks.
Publications by Year: 2025
2025
Schendel, Sharon L, Xiaoying Yu, Peter J Halfmann, Jarjapu Mahita, Brendan Ha, Kathryn M Hastie, Haoyang Li, et al. (2025) 2025. “A Global Collaboration for Systematic Analysis of Broad-Ranging Antibodies Against the SARS-CoV-2 Spike Protein.”. Cell Reports 44 (4): 115499. https://doi.org/10.1016/j.celrep.2025.115499.
Schami, Alyssa, Nurul Islam, Matthew Wall, Amberlee Hicks, Reagan Meredith, Barry Kreiswirth, Barun Mathema, John T Belisle, and Jordi B Torrelles. (2025) 2025. “Publisher Correction: Drug Resistant Mycobacterium Tuberculosis Strains Have Altered Cell Envelope Hydrophobicity That Influences Infection Outcomes in Human Macrophages.”. Scientific Reports 15 (1): 8567. https://doi.org/10.1038/s41598-025-93606-0.